{"id":"W4400143131","doi":"10.1016/j.annonc.2024.05.176","title":"167P Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)","year":2024,"lang":"fr","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"Sirtex Medical; Ipsen; Astellas Pharma; Eisai; Incyte; Boston Scientific Corporation; Gilead Sciences; Exelixis; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Durvalumab; Tremelimumab; Medicine; Hepatocellular carcinoma; Internal medicine; Carcinoma; Oncology; Gastroenterology; Immunotherapy; Cancer; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007070639,0.0006102278,0.0009543402,0.0001944351,0.0004106383,0.0009447816,0.0003968112,0.0003921698,0.001689664],"category_scores_gemma":[0.0006778309,0.0003206053,0.0009735025,0.0004325896,0.0003855246,0.0003455548,0.0003489289,0.0009957597,0.0002844973],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007175127,"about_ca_system_score_gemma":0.001081432,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00397521,"about_ca_topic_score_gemma":0.006823506,"domain_scores_codex":[0.9996829,0.0001572168,0.00001568476,0.00003480778,0.00003326022,0.00007608987],"domain_scores_gemma":[0.9996518,0.00005888822,0.00007304009,0.00004771416,0.00002987254,0.000138626],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.58342,0.005502701,0.3133062,0.0007378629,0.01005371,0.0009567762,0.0005055034,0.001367134,0.0232423,0.000586208,0.004180109,0.05614131],"study_design_scores_gemma":[0.1479045,0.05309727,0.7749972,0.000121327,0.008509453,0.00143189,0.0004915891,0.001422648,0.004118297,0.0005312822,0.007296877,0.00007770707],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970787,0.0009173358,0.000112511,0.0001748693,0.00004342665,0.0002168369,0.000734311,0.000007686855,0.0007144961],"genre_scores_gemma":[0.9968296,0.0004053018,0.0002625705,0.0002579736,0.00005586429,0.0001968697,0.001343709,0.000005556629,0.0006425937],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00397521,"threshold_uncertainty_score":0.007904172,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1271803113158612,"score_gpt":0.3652423502696358,"score_spread":0.2380620389537746,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}